Project Grant R61NS136569

Award Date 9/18/24
Completion Date 8/31/26
Dollars Obligated $775K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on validating a translational rat model of chronic discogenic low back pain. The primary goal is to reproduce and validate a recently published rat model of disc degeneration-induced low back pain in an external laboratory to demonstrate replicability and establish the model's overall validity. The $366,975 grant will fund...
This federal Project Grant award, issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $534,382 to the Cedars-Sinai Medical Center to conduct research focused on understanding the mechanism of discogenic low back pain induction. The key objectives of this 5-year project (June 2024 to May 2029) are to: Identify the cellular sub-populations that transform...
This Project Grant award from the National Institute of Neurological Disorders and Stroke, under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a novel non-invasive high frequency trans-spinal magnetic stimulation (HF-TSMS) system for the treatment of neuropathic pain. The $3,565,780 grant supports experimental studies using rodent models at Massachusetts General Hospital (MGH) to assess pain responses via fMRI, as well as further efficacy and safety evaluations in...
This $2,103,564 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to investigate the cellular mechanisms and therapeutic potential of the nuclear receptor NR4A1 in pain resolution. The grant will fund research to test whether NR4A1 in macrophages controls the resolution of inflammation and postoperative pain, whether NR4A1 agonists can promote pain resolution, and whether NR4A1...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $658,385 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to the Regents of the University of Minnesota to conduct research on the role of DNA methylation in intervertebral disc degeneration and chronic low back pain. The research aims to identify the DNA methylation and gene expression landscape associated with discogenic low back pain in both human subjects and...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to explore the unknown function of the LRRC55 protein in pain processing. The $444,125 award, spanning from September 2024 to August 2026, will support research conducted by Duke University to: Delineate the role of LRRC55 in chronic pain behaviors using genetically modified mice; 2) Quantify functional changes in LRRC55...
This federal Project Grant award of $2,073,990.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279) grant, aims to establish and validate a novel animal model of fibromyalgia (FM). The award to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), will fund the standardization and assessment of behavioral tests in genetically modified mice lacking the enzyme intestinal...
This National Institute of Neurological Disorders and Stroke (NINDS) Project Grant award of $242,061.00 under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the establishment of the Mass General Brigham Interdisciplinary Clinical Pain Research Training Program. This program will provide a 2-3 year training and research experience for a diverse pool of postdoctoral fellows, with the goal of expanding the cadre of early-career clinical pain researchers capable of launching...
This federal Project Grant award of $605,253 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the mechanical crosstalk between the intervertebral disc and facet joints during spinal degeneration and repair. The project aims to 1) characterize the progression of facet osteoarthritis following experimentally-induced disc degeneration in a large animal...
This $5,037,022 project grant from the National Institutes of Health's National Institute of Neurological Disorders and Stroke will support the development of novel single-cell technologies called "Raman2omics" to map pain-associated genes and cells across the lifespan. Funded under the Drug Abuse and Addiction Research Programs, the grant to the Massachusetts General Hospital aims to apply Raman2omics to systematically investigate genes and cells associated with postoperative pain...

This federal Project Grant award, totaling $774,930, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant aims to develop and validate a clinically representative mouse model of intervertebral disc degeneration-induced low back pain to facilitate the discovery of novel, non-addictive analgesics.

The key products or services to be delivered under this 2-year R61 and 1-year R33 award include: 1) optimizing a cross-breeding protocol to reproduce the behavioral, radiographic, and cellular/molecular characteristics of clinical discogenic low back pain using an inducible, disc-specific SPARC deletion model; 2) validating the behavioral phenotype of the model and determining its responsiveness to pharmacological interventions like morphine, pregabalin, and ibuprofen; and 3) independent replication of the validated model at the University of New England. This research aims to provide a preclinical model that better represents the human condition of discogenic low back pain, enabling the discovery and validation of new non-addictive pain therapeutics.

Generated 5/13/25, 4:03 AM